At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 6 enrolled
Drug / intervention
sugammadex +1 moredrug
Likely dose
sugammadex 4.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Open-Label Trial in Subjects With Severe Renal Impairment Evaluating the Dialysability of the Sugammadex-Rocuronium Complex
In Brief
A Phase 3 clinical trial evaluating sugammadex and Rocuronium for Neuromuscular Blockade. Completed, enrolled 6 participants.
Detailed Summary
The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedApr 11, 2008
Enrollment StartApr 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.2 years ago
Interventions
sugammadexdrug
At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
Rocuroniumdrug
After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered